News for Y-mAbs Therapeutics, Inc. (YMAB)

Total Revenue: $87.7 million for the full year 2024.DANYELZA Net Product Revenues: $85.2 million for the full year 2024; $24.5 million for Q4 2024, a 5% increa

Mar 04, 2025 / 01:00PM GMTOperator Good morning and welcome to Y-mAbs Therapeutics Inc's earnings conference call for the fourth quarter in full year 2024. (Ope

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2024 Earnings Conference Call March 4, 2025 8:00 AM ETCompany ParticipantsCourtney Dugan - Head-IRMichael Rossi -...

California-based GigaCloud Technology Inc. (GCT) is down over 21 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

YmAbs Therapeutics (YMAB) delivered earnings and revenue surprises of -15.38% and 0.40%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Revenue: $26.5 million for Q4 2024, slightly below the estimated $27.29 million, but marking a 13% increase year-over-year.Annual Revenue: $87.7 million for 20

Reported Total Revenues of $26.5 million for the fourth quarter of 2024 and $87.7 million for the full year 2024 The Company established two business units in J

Naxitamab demonstrated clinically meaningful efficacy with manageable safety in patients with relapsed/refractory high-risk neuroblastoma and residual disease

**media[555351]**

Y-mAbs Therapeutics Inc (YMAB) is set to release its Q4 2024 earnings on Mar 4, 2025. The consensus estimate for Q4 2024 revenue is $27.29 million, and the earn

**media[546126]**

**media[528982]**

Financial writer recommends buying YMAB stock despite declining sales and uncertainty in radiotherapy platform, pending upcoming data. Click here to read.

Y-mAbs Therapeutics reported FY 2024 revenue slightly below estimates. Shares down 2.4%.

**media[511801]**

NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the ”œCompany” or ”œY-mAbs”) ( YMAB), a commercial-stage biopharmaceutical compan

Company establishes two business units with goal of accelerating the advancement of its Radiopharmaceuticals Platform and optimizing the commercial potential of

**media[499473]**

Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting